Maravai Lifesciences Holdings (MRVI) Net Income towards Common Stockholders (2020 - 2026)

Maravai Lifesciences Holdings' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$6.4 million for Q1 2026.

• In Q1 2026, Net Income towards Common Stockholders rose 87.93% year-over-year to -$6.4 million; the TTM figure through Mar 2026 stood at -$184.3 million (up 36.41% YoY), while the FY2025 annual figure was -$230.8 million, up 11.12% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$6.4 million, up from -$63.0 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $156.7 million in Q2 2022, with the low at -$172.5 million in Q3 2024.
• The 5-year median for Net Income towards Common Stockholders is -$18.4 million (2024), against an average of -$8.5 million.
• The sharpest annual moves came in 2022 and 2024: Net Income towards Common Stockholders surged 94.61% in 2022, then sank 1582.49% in 2024.
• Maravai Lifesciences Holdings' Net Income towards Common Stockholders stood at $87.4 million in 2022, then plunged by 225.8% to -$110.0 million in 2023, then jumped by 58.11% to -$46.1 million in 2024, then sank by 36.79% to -$63.0 million in 2025, then jumped by 89.88% to -$6.4 million in 2026.
• Business Quant data shows MRVI's Net Income towards Common Stockholders at -$6.4 million in Q1 2026, -$63.0 million in Q4 2025, and -$45.1 million in Q3 2025.